Effect of Nisoldipine and Olmesartan on Endothelium‐Dependent Vasodilation in Essential Hypertensive Patients

摘要

SUMMARY Aims: To investigate whether nisoldipine and olmesartan improve endothelial function, decrease asymmetric dimethylarginine (ADMA) and alleviate the inflammatory and oxidative process. Methods: Fifty‐five essential hypertensive patients were randomized to receive nisoldipine or olmesartan for 8 weeks according to a parallel‐group, active‐controlled, single blind study, and 28 matched normotensive subjects served as healthy controls. Flow‐mediated dilation (FMD), and plasma levels of nitric oxide (NO), endothelin‐1 (ET‐1), high‐sensitive C‐reactive protein (hs‐CRP), 8‐isoprostane (also named 8‐isoPGF2α), and ADMA were determined. Results: At baseline, the plasma levels of ADMA, ET‐1, hs‐CRP, and 8‐isoPGF2α were markedly higher in patients with essential hypertension than in normotensive subjects ( P Conclusion: The findings demonstrate that nisoldipine and olmesartan both improve FMD in patients with essential hypertension. This may be associated with decreased circulating levels of CRP, ET‐1, and ADMA.